Johnson & Johnson (NYSE:JNJ) Shares Purchased by Clarity Wealth Advisors LLC

Clarity Wealth Advisors LLC raised its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,195 shares of the company’s stock after purchasing an additional 357 shares during the quarter. Johnson & Johnson comprises approximately 2.0% of Clarity Wealth Advisors LLC’s portfolio, making the stock its 18th largest holding. Clarity Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,299,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. RKL Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 2.1% in the second quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after purchasing an additional 1,010 shares in the last quarter. Geller Advisors LLC increased its position in shares of Johnson & Johnson by 7.5% in the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after acquiring an additional 648 shares in the last quarter. Simon Quick Advisors LLC increased its position in shares of Johnson & Johnson by 296.9% in the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after acquiring an additional 6,537 shares in the last quarter. Lokken Investment Group LLC increased its stake in Johnson & Johnson by 1.6% during the 2nd quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after buying an additional 201 shares during the period. Finally, Keebeck Alpha LP increased its stake in Johnson & Johnson by 13.4% during the 2nd quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after buying an additional 525 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $168.31 on Tuesday. The firm has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. The stock’s 50 day moving average is $176.07 and its 200-day moving average is $171.13. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Analysts Set New Price Targets

Several research analysts have recently commented on JNJ shares. Atlantic Securities decreased their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. SVB Leerink dropped their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday. Citigroup boosted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Sanford C. Bernstein decreased their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Finally, Morgan Stanley cut their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $181.75.

Insider Buying and Selling

In related news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the transaction, the executive vice president now owns 41,813 shares in the company, valued at $7,336,927.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 233,611 shares of company stock valued at $40,960,735. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.